1513860-02-0

Basic information

• Product Name: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3‘,2’: 5,6]pyrido[4,3-d]pyrimidin-2-one
• Synonyms: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3‘,2’: 5,6]pyrido[4,3-d]pyrimidin-2-one
• CAS NO: 1513860-02-0
• Molecular Weight: 627.669
• Mol File: 1513860-02-0.mol

Chemical Properties

• CAS DataBase Reference: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3‘,2’: 5,6]pyrido[4,3-d]pyrimidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3‘,2’: 5,6]pyrido[4,3-d]pyrimidin-2-one(1513860-02-0)
• EPA Substance Registry System: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3‘,2’: 5,6]pyrido[4,3-d]pyrimidin-2-one(1513860-02-0)

Safety Data

• Hazardous Substances Data: 1513860-02-0(Hazardous Substances Data)

Upstream product

• 36629-42-2 methyl pentafluorobenzoate 
• 55052-28-3 4-chloro-7-azaindole 

Downstream Products

• 1513857-77-6 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3’,2’:5,6]pyrido[4,3-d]pyrimidin-2-one 

Relevant articles and documents

DERIVATIVES OF AN FGFR INHIBITOR

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME

The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.